###### Significance of this study

What is already known on this subject?
======================================

-   Effect of Tight Control Management on  Crohn's Disease was the first study to show that a biomarker-based and clinical symptom-based monitoring strategy (ie, tight control   strategy (TC)) resulting in timely modification of adalimumab-based therapy prompts better endoscopic and clinical outcomes than relying on the conventional symptom-driven treatment strategy (CM) in patients with Crohn's disease (CD) naïve to immune suppressants and biologics.

What are the new findings?
==========================

-   TC is cost-effective compared with CM. TC is associated with fewer hospitalisations and more time in remission. Total costs are higher in TC due to greater use of adalimumab and biomarker testing than CM but are offset by reduced hospitalisations and quality-adjusted life years gained, resulting in a cost-effectiveness ratio that indicates good value for money in the UK setting relative to published National Institute for Health and Care Excellence guidances.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Physicians should consider using an inflammatory biomarker-based and clinical symptom-based monitoring strategy to inform their treatment decisions for patients with moderate to severe active CD, given that TC is associated with superior efficacy compared with CM and is a cost-effective use of resources.

Introduction {#s1}
============

Crohn's disease (CD) is a chronic, disabling, progressive inflammatory disease of the gastrointestinal tract in which patients may develop strictures, abscesses or fistulas.[@R1] Costs associated with CD are substantial.[@R2] A review article estimated that the annual hospitalisation incidence due to CD was 20%, half of patients with CD required surgery within 10 years after diagnosis and the risk of postoperative recurrence was 44% to 55% after 10 years.[@R3] Severe CD has also been related to lower quality-of-life and work productivity, with indirect costs representing a substantial portion of the costs of CD.[@R4] Direct costs were primarily driven by hospitalisation prior to the widespread use of biologics such as tumour necrosis factor inhibitors; biologic therapy is now the primary driver of direct costs.[@R6] Despite the costs, biologic use is associated with significant improvement in efficacy and disease control compared with conventional therapy such as corticosteroids and immunomodulators. However, current treatment algorithms rely on symptoms alone to inform decisions which may delay initiation of the most effective treatment.[@R8] These approaches may prolong use of corticosteroids and put patients at risk of infections, morbidity and mortality.[@R9] A recent consensus stated that inflammatory biomarkers, such as faecal calprotectin (FC) and C-reactive protein (CRP), might be useful in detecting intestinal inflammation and could inform treatment adjustment.[@R11]

The Effect of Tight Control Management on Crohn's Disease (CALM) trial was a randomised, controlled, open-label, phase 3 study in 22 countries that assessed whether a tight control treatment strategy (TC) using inflammation biomarkers FC and CRP in addition to clinical symptoms to direct therapy was superior to conventional practice that did not rely on biomarkers to direct therapy, namely clinical management (CM) in early CD.[@R12] The CALM trial evaluated adult patients with active endoscopic CD, a CD Activity Index (CDAI) of 150--450 depending on dose of prednisone at baseline and no previous use of immunomodulators or biologics. Detailed study design was published elsewhere.[@R12]

CALM was the first study to show that a TC monitoring strategy and timely treatment modification with adalimumab-based therapy results in better clinical and endoscopic outcomes than conventional symptom-driven treatment strategy in patients with early CD. TC was associated with significant improvements in mucosal healing (defined as Crohn's disease endoscopic index of severity (CDEIS) \<4 and no deep ulcers), deep remission and steroid-free remission in TC than CM at week 48.[@R12]

Costs associated with TC may include more frequent biomarker tests and biologic use. However, the clinical benefit of mucosal healing and deep remission associated with TC could also affect economic outcomes such as hospitalisation and work productivity gain, which can reduce healthcare and societal costs. This study aimed to analyse the hospitalisation and work productivity outcomes in CALM and examine the cost-effectiveness (CE) of TC and CM treatment strategies in an economic model using data from the CALM trial.

Methods {#s2}
=======

Model structure {#s2a}
---------------

We developed a state transition (or Markov) model to compare TC and CM strategies with a UK public payer perspective using patient-observation data from the CALM trial, including the TC (n=122) and CM (n=122) groups.[@R12] State transition models represent disease severity by health states defined by clinically-relevant severity measures. Patients in the model can transition from one health state to another based on transition probabilities. We based our health states on CDAI scores, which included remission (CDAI \<150), moderate (CDAI ≥150 to \<300), severe (CDAI ≥300 to \<450) and very severe (CDAI ≥450) with hospitalisation as a toll state (online [supplementary figure S1](#SP1){ref-type="supplementary-material"}). A sensitivity analysis was assessed including a mild state (CDAI ≥150 to 220) (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}). Both 48-week and 5-year time horizons were modelled. Models using these health states are based solely on disease activity, exclude opaque aspects of treatment response (eg, 'drug responsive')[@R13] and have been published previously.[@R14]
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Data {#s2b}
----

CALM trial data were analysed to derive model inputs for baseline health states, transition probabilities between health states, hospitalisation rates conditional on health states, adalimumab injections and indirect costs in terms of absenteeism (missed hours of work) due to CD. Wilcoxon rank-sum tests and χ^2^ tests compared continuous and categorical variables, respectively, in the TC and CM arms at baseline. Initial health state distribution was based on the pooled samples' CDAI scores.

CDAI was measured at weeks 0, 2, 6, 11, 23, 35 and 48 in the CALM trial. Patients were mapped into health states based on their CDAI at each observation. The model used an intent-to-treat (ITT) approach. Missing CDAI values or censored values were imputed using the last-observation-carried-forward approach.

Transition probabilities {#s2c}
------------------------

A regression model, specifically an ordered probit model, estimated weekly transition probabilities among health states. An ordered probit model allows for an outcome with multiple ordered categories (eg, remission, moderate, severe and very severe). A simple regression was estimated with a treatment variable (TC or CM) to assess the treatment effect. To allow treatment effects to vary across health states and over time, the model used a specification where the treatment variable interacted with lagged health states. The model included covariates for time since last CDAI measure and a pre/post-week-23 dummy variable that corresponded to the peak clinical remission rates observed in CALM to improve extrapolation of outcomes outside the 48-week trial. All regressions employed robust standard errors clustered at the patient level. Predicted health state distributions were linearly interpolated between trial observations to derive weekly health state distributions. In sensitivity analysis, observed CDAI-based health state distributions were used instead of predicted distributions. Proportion of time in remission was calculated as the number of weeks in remission divided by total modelled weeks.

Direct medical costs {#s2d}
--------------------

Direct medical costs comprised hospitalisation, other direct medical costs (including laboratory, radiology, emergency department, non-biologic drugs, physician consults and outpatient visits), adalimumab injections and biomarker tests using UK prices. The crude rate of CD-related hospitalisations observed in the CALM trial was reported in events per patient year for TC and CM. Cumulative hospital incidence and a simple probit were also estimated to assess the treatment effect. In the CE model, inputs of CD-related hospitalisation events were estimated from a multivariate probit model (using similar specifications as the ordered probit model for health states). CD-related hospitalisation costs were derived based on inpatient costs that stratified patients by disease severity.[@R7]

Estimates for other direct medical costs were derived from published research that stratified patients by disease severity.[@R16] Costs of adalimumab were estimated using observed injections from the CALM trial and NHS prices from 2017.[@R17] Patients in the TC group received CRP and FC tests at weeks 0, 11 and every 12 weeks thereafter; costs included test costs, staff time and reader costs.[@R18] All cost inputs were inflation adjusted to 2016/17 prices using the hospital community health services index.[@R20]

Indirect costs/costs associated with absenteeism {#s2e}
------------------------------------------------

The Work Productivity and Activity Impairment (WPAI) questionnaire assessed subjects' ability to work and perform daily activities in terms of absenteeism due to CD at weeks 0, 11, 23, 35 and 48.[@R21] The effect of TC relative to CM was determined using an ordinary least squares model of the change in the percentage of missed hours out of a work week relative to baseline. Absenteeism was monetised using an average 2017 UK wage rate from the Office of National Statistics.[@R22] Absenteeism was included in sensitivity analysis reflecting the average effect on costs for the total CALM sample.

Health utility {#s2f}
--------------

Quality-of-life was measured in the trial with the 36-Item Short Form Health Survey instrument at the same time points as the WPAI.[@R23] Scores were transformed to Short-Form Six-Dimension (SF-6D) utilities.[@R24] SF-6D scores that are transformed have been shown to have a smaller range and lower variance in values and floor effects.[@R25] We used EQ-5D-based health utility from a larger study relating CDAI to estimate health state utility for the base case.[@R26] We used the trial-based SF-6D-based estimates in a sensitivity analysis.

Presentation of final results {#s2g}
-----------------------------

Cost-utility outcomes were calculated, including incremental CE ratio (ICER), incremental net monetary benefit (INMB), quality-adjusted life-years (QALYs) monetised at £30 000 each and CE acceptability curves (CEAC). We conducted one-way sensitivity analyses on key variables to examine how results varied over plausible input ranges which were identified in the literature or via analysis of the CALM trial. This analysis re-runs our base-case model while individually varying the selected variables within defined input ranges, to provide an idea of how much certain parameters influence the ICER ([table 1](#T1){ref-type="table"}). The base-case analysis was also estimated outside the trial horizon to 2 and 5 years using modelling prediction based on 48-week data from the CALM trial. To account for the uncertainty in all model parameters simultaneously, we conducted a probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations, which re-runs our primary analysis while varying parameter values simultaneously based on their distributions ([table 1](#T1){ref-type="table"}). We used the Cholesky decomposition of the covariance matrices from the multivariate regressions to account for correlated inputs in the probabilistic sensitivity analysis.[@R27]

###### 

Model inputs and values used in SA

                                                    Mean      SE      Alpha   Beta   Distribution   High value in one-way SA   Low value in one-way SA   Source
  ------------------------------------------------- --------- ------- ------- ------ -------------- -------------------------- ------------------------- -------------
  CD-related hospitalisation costs, per admission   £8573     3429    6       1372   Gamma          £10 288                    £6859                     [@R7]
  Other direct medical costs, weekly\*                                                                                                                   
   Remission (CDAI \<150)                           £15       4       12      1      Gamma          £23                        £0                        [@R16]
   Moderate (CDAI ≥150 to \<300)                    £42       8                      Gamma          £58                        £0                        [@R16]
   Severe (CDAI ≥300 to \<450)                      £66       13                     Gamma          £91                        £40                       [@R16]
   Very severe (CDAI ≥450)                          £66       13                     Gamma          £91                        £40                       [@R16]
  Adalimumab, cost per 40 mg injection              £352.14   None    None    None   None           None                       £176.07                   [@R17]
  CRP test                                          £1.97     None    None    None   None           £5.53                      £1.97                     [@R18]
  FC test                                           £23.27    None    None    None   None           £67.93                     £23.27                    [@R18]
  Health utility, annual                                                                                                                                 
   Remission (CDAI \<150)                           0.827     0.008   1747    366    Beta           0.843                      0.810                     [@R26]
   Moderate (CDAI ≥150 to \<300)                    0.647     0.008                  Beta           0.663                      0.630                     [@R26]
   Severe (CDAI ≥300 to \<450)                      0.467     0.008                  Beta           0.483                      0.450                     [@R26]
   Very severe (CDAI ≥450)                          0.287     0.008                  Beta           0.303                      0.270                     [@R26]
  Baseline CDAI state distribution                                                                                                                       
   Remission (CDAI \<150)                           0                                                                                                    CALM[@R12]†
   Moderate (CDAI ≥150 to \<300)                    0.742             181     63     Dirichlet      1                          0                         CALM[@R12]†
   Severe (CDAI ≥300 to \<450)                      0.254             62      182    Dirichlet      0                          0.5                       CALM[@R12]†
   Very severe (CDAI ≥450)                          0.004             1       243    Dirichlet      0                          0.5                       CALM[@R12]†

Transition probability, hospitalisation and absenteeism point estimates were for base-case analysis, parameters for one-way and probabilistic sensitivity analyses based on regression in online [supplementary table S1](#SP1){ref-type="supplementary-material"}.

\*National Health Service paid costs except hospitalisation and adalimumab.

†CALM trial data analysis.

CALM, Effect of Tight Control Management on Crohn's Disease trial; CD, Crohn's disease; CDAI, Crohn's Disease Activity Index; CRP, C-reactive protein; FC, faecal calprotectin; SA, sensitivity analysis.

Results {#s3}
=======

The distribution of TC and CM arms across CDAI-based health states was not statistically significantly different at baseline (online [supplementary table S1](#SP1){ref-type="supplementary-material"}). The pooled distribution across CDAI-based health states at baseline was 74.2% moderate, 25.4% severe and 0.4% very severe. The ordered probit regression (online [supplementary table S2](#SP1){ref-type="supplementary-material"} for simple specification and online [supplementary table S3](#SP1){ref-type="supplementary-material"} for model specification) indicated that TC had a greater likelihood of patients maintaining or moving to a less severe health state; the Markov matrices estimated from these regressions and used in the model appear in online [supplementary table S4](#SP1){ref-type="supplementary-material"}.

TC-treated patients had 14 CD-related hospitalisations over 106.3 patient years (13.2 per 100 patient years) at week 48; CM-treated patients had 29 CD-related hospitalisations over 103.6 patient years (28.0 per 100 patient years, p=0.021). The hospitalisation rate from the regression analysis of CALM data indicated that more severe health states were associated with greater likelihoods of hospitalisation, and that TC was associated with a lower likelihood of hospitalisation (beta: −0.247, p=0.037, online [supplementary table S2](#SP1){ref-type="supplementary-material"}). Cumulative incidence of hospitalisation appears in [figure 1](#F1){ref-type="fig"}; in the ITT model, TC patients were predicted to have 0.124 CD-related hospitalisations compared with 0.297 for CM over 48 weeks.

![Observed and predicted cumulative incidence of CD-related hospitalisations. Cumulative incidence of CD-related hospitalisation based on observed cumulative hospitalisations in CALM (A) and modelled cumulative hospitalisations (B) based on regression in online [supplementary table S3](#SP1){ref-type="supplementary-material"}. CALM, Effect of Tight Control Management on Crohn's Disease trial; CD, Crohn's disease; ITT, intent-to-treat.](gutjnl-2019-318256f01){#F1}

The absenteeism regression, estimated with a sub-sample (n=129) who recorded WPAI responses, revealed that TC was associated with a greater reduction of 5.6% in missed hours compared with baseline relative to CM over 48 weeks, although results were not statistically significant (beta: −5.606, p=0.346 in simple model, online supplementary [table S2](#SP1){ref-type="supplementary-material"}).

The summary CE results over 48 weeks appear in [table 2](#T2){ref-type="table"}. The model predicted that 58.2% of patients' 48 weeks were in clinical remission under the TC strategy, compared with 46.8% in the CM arm. TC-treated patients had 0.124 predicted hospitalisations per patient, CM had 0.297, resulting in £1462 lower hospitalisation costs for TC-treated patients versus CM patients. Other direct medical costs were £224 lower for TC than CM patients. Mean adalimumab injections were 31.01 in TC and 24.74 in CM, which increased TC costs by £2170. The cost of CRP and FC testing increased TC costs by £109. QALYs were higher by 0.032 for TC patients. The ICER was £18 656 per QALY, or £360 INMB, in the base case which excluded absenteeism.

###### 

Results of cost-effectiveness evaluation over 48-week analysis

  Outcome                                                    TC        CM        Incremental (TC--CM)
  ---------------------------------------------------------- --------- --------- ----------------------------------
  Proportion of time in remission                            0.582     0.468     0.114
  Hospitalisation events per patient                         0.124     0.297     −0.173
  Adalimumab injections, 40 mg                               31.01     24.74     6.27
  Direct medical costs                                                           
   Adalimumab costs                                          £10 770   £8601     £2170
   CRP and FC testing costs                                  £109      £0        £109
   Hospitalisation costs                                     £1044     £2506     −£1462
   Other direct medical costs                                £1332     £1556     −£224
  Total costs                                                £13 255   £12 662   £593 (95% CI: £−12 952 to £2096)
  Total QALYs                                                0.668     0.636     0.032 (95% CI: 0.011 to 0.055)
  ICER (excluding absenteeism)                                                   £18 656
  Incremental net monetary benefit (excluding absenteeism)                       £360
   Change in absenteeism                                     −£3962    −£2748    −£1214
  ICER (including absenteeism)                                                   TC dominant
  Incremental net monetary benefit (including absenteeism)                       £1575

CM, Clinical management strategy; CRP, C-reactive protein; FC, faecal calprotectin; ICER, incremental cost-effectiveness ratio.; QALY, quality-adjusted life-year; TC, tight control strategy.

TC reduced absenteeism by £3962, versus −£2748 for CM, which equates to about 77.5 more hours of work over 48 weeks per patient for TC. When absenteeism was included in the analysis, TC was the dominant treatment strategy (meaning less costly and more effective than CM), with £1575 INMB.

The results of the one-way sensitivity analysis appear in [figure 2](#F2){ref-type="fig"}. Model results were most sensitive to the baseline distribution of patients among CD severity levels, the inclusion of absenteeism, the costs of adalimumab and the health utility inputs. If all patients were in the moderate state at model baseline, the ICER was £29 695 per QALY, indicating that TC was still preferred to CM but only marginally. If half of patients were severe and half very severe at baseline, TC was more effective and less costly (ie, dominant) versus CM. The incremental costs of TC versus CM became negative (ie, less costly for TC) when including the costs related to absenteeism or when costs of adalimumab were reduced by ≥30%, at which point TC become dominant. Using SF-6D converted health utilities resulted in an ICER of £50 910 per QALY, suggesting that, counter to the base case, the CM strategy was more cost-effective than a TC strategy. If absenteeism was included and SF-6D utilities used, TC was dominant (£306 INMB). Modelling the base case beyond the end of the 48-week horizon by use of the Markov matrices estimated by the regression model indicated that TC was more cost-effective at year 2 (£12 166 per QALY) and year 5 (£10 675 per QALY). The sensitivity analysis including a mild state resulted in a £20 991 per QALY ICER (online supplementary appendix). The results of the PSA are displayed as a CEAC in [figure 3](#F3){ref-type="fig"}. The CEAC indicated that 57.9% of simulations were below an ICER of £30 000 per QALY in the base case (excluding absenteeism); 81.8% were below the same threshold when including absenteeism.

![One-way sensitivity analysis of tight control versus clinical management base-case analysis. Values in base case and sensitivity analyses appear in [table 1](#T1){ref-type="table"}. CALM, Effect of Tight Control Management on Crohn's Disease trial CDAI, Crohn's disease Activity Index; ICER,  incremental cost-effectiveness ratio;  NHS, National Health Service; SA, sensitivity analysis.](gutjnl-2019-318256f02){#F2}

![Cost-effectiveness acceptability curves (CEAC) of tight control versus clinical management excluding (base case) and including absenteeism due to Crohn's disease (CD) effects. To illustrate the uncertainty surrounding incremental cost-effectiveness ratio (ICER) estimates, the CEACs depict the probability that the tight control   strategy (TC) strategy is preferred to the clinical management (CM) strategy across a range of cost-effectiveness ratios. Results are depicted for the analysis excluding absenteeism (hashed lines) and including absenteeism (solid grey line). Results are based on the probabilistic sensitivity analysis, which included 1000 second-order Monte Caro simulations in which model variables were simultaneously varied. The solid black vertical line indicates the £30 000 per quality-adjusted life-years (QALY) willingness-to-pay threshold commonly used as a benchmark in the UK. 57.9% of simulations were at the threshold when excluding absenteeism, indicating that TC was likely better value considering costs and QALYs than CM; 81.8% were below the threshold when including absenteeism, indicating TC was more probably good value versus CM in that scenario.](gutjnl-2019-318256f03){#F3}

Discussion {#s4}
==========

Although biologic use is a large component of CD treatment costs, our study showed that use of adalimumab with a TC management strategy brings significant clinical benefit in a cost-effective way on a clinical and societal level. Using a model-based approach adopting data from the CALM trial, our study suggests that a TC strategy is cost-effective at traditional thresholds used by National Institute for Health and Care Excellence (ICERs below £20 000 to £30 000 per QALY).[@R28] We found that the costs associated with greater use of adalimumab and additional CRP and FC testing in the TC strategy were offset by improvement in remission, reductions in CD-related hospitalisation and improvements in quality of life, which included resumed work productivity. Results were generally robust to sensitivity analyses, indicating that model estimates were reliable.

CALM incorporated economic endpoints and appropriate follow-up time for assessment of economic effects. It was not an event-based study or otherwise set up to hinder an ITT analysis.[@R29] We maximised the patient-observation level data in the base case, using both modelled health states based on CDAI observations and unmodelled CDAI states in sensitivity analysis. Several resources not measured in the trial, including outpatient visits, emergency department, physician consults, radiology, comprehensive laboratory and non-biologic drugs were sourced from a study that stratified resource use by disease severity.[@R16] The base-case analysis reflected the complete trial study period; sensitivity analysis projected observed trends outcomes onto longer time horizons.

The TC-based treatment strategy is cost-effective even though it involved greater adalimumab and testing use that lead to higher direct medical costs than conventional CM. In threshold analyses, the TC-based strategy would become not cost-effective if the adalimumab price increased by 16.6% to £410.64 per injection or if the FC test price were 358% above the base-case input (£106.77 per test) in the UK setting. However, adalimumab cost is expected to decrease in anticipation of biosimilar therapy, which would increase the likelihood of CE of TC versus CM, as shown in sensitivity analysis. Another key component of cost is hospitalisation episodes due to CD. In the trial, TC had a greater than 50% reduction in CD-related hospitalisation, offsetting some of the increased direct medical costs. When the time horizon of the model was adjusted to two and 5 years, the ICER decreased. Thus, the additional biologic and testing costs could be offset by further hospitalisation decrease at the margin.

The cost of absenteeism due to CD was the sole indirect cost included in the model. The WPAI included several other potentially monetisable endpoints, including impairment while working, overall work impairment and activity impairment. Across each WPAI measure, TC showed greater reductions in impairment than CM in every within-group (comparing study week versus baseline WPAI outcomes) and between-group comparison at week 11, 23, 35 and 48; however, the between-group changes were not significant at an alpha of 0.05 with one exception. CALM may not have been powered to assess WPAI differences as only about half the participants were working at baseline. When including lost earnings from absenteeism due to CD using UK wage rates, the effects were large relative to direct medical costs. TC was dominant when these costs were included. These results are likely conservative as they excluded other measures of indirect cost.

If a biomarker-based and clinical symptom-based treatment strategy were superior to conventional CM in terms of efficacy, safety, quality of life and cost, will it replace CM as the new treatment paradigm? The results from this research could facilitate adoption of the TC practice style in the UK and perhaps other countries. There remain barriers to the adoption of new treatment strategies even when supported with trial-based evidence. Reimbursement for the FC test varies across primary care trusts in the UK. Diffusion of the TC practice pattern could be challenging in localities where the FC test is not reimbursed. Additionally, a new treatment strategy requires surmounting physician inertia to continue conventional practice patterns. Not modifying practice styles out of habit despite sound clinical and economic evidence to the contrary has been shown to be a major factor slowing uptake of new practice patterns.[@R30]

There are limitations to this analysis. The CALM study population had early CD (median 2.61 months disease duration for both arms) which may not be generalisable to patients who have longer treatment histories. As a randomised controlled trial, observations from CALM came from an experimental setting, and may not be representative of typical patients with CD. This study used prices and a CE approach appropriate for the UK which may not be transferable to other countries. Extrapolated results beyond the trial horizon per the sensitivity analysis cannot be externally validated. This analysis also focuses on average effects in the study population. Future research could evaluate whether some sub-groups may benefit more from TC.

Conclusion {#s5}
==========

Using CALM trial data, this study was the first to assess and demonstrate that use of adalimumab in a TC approach with both biomarker-based and clinical symptom-directed strategy is cost-effective compared with CM from the UK perspective.

Medical writing support was provided by Suchin Virabhak and Julia Bond, Medicus Economics LLC, Boston, Massachusetts, USA.

**Contributors:** RP, J-FC, SPLT, PB, FB, TV, AD, GN, AA, WR, EN, JP, GD'H, W-JL: Study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; study supervision. SJ, MB: Study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; administrative, technical, or material support; study supervision. RP, J-FC, SPLT, PB, FB, TV, AD, GN, AA, WR, EN, JP, GD'H, W-JL, SJ, MB: approved the final draft submitted.

**Funding:** Financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review and approval of the publication. All authors contributed to the development of the publication and maintained control over the final content.

**Competing interests:** RP has received consultant and/or lecture fees from AbbVie, Amgen, AstraZeneca, Axcan Pharma (now Aptalis), Biogen Idec, Bristol-Myers Squibb, Centocor, ChemoCentryx, Eisai Medical Research Inc, Elan Pharmaceuticals, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck Sharp & Dohme Corp, Millennium Pharmaceuticals Inc (now Takeda), Ocera Therapeutics Inc, Otsuka America Pharmaceutical, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Schering-Plough Corporation, Synta Pharmaceuticals Corp, Teva, UCB Pharma and Warner Chilcott. J-FC has been a consultant or advisory board member for AbbVie, Amgen, Boehringer-Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, Genentech, Janssen and Janssen, Medimmune, Merck & Co, Pfizer, Protagonist, Second Genome, Seres, Shire, Takeda, Theradiag, speaker for AbbVie, Ferring, speaker's bureau for Amgen, stock options of Intestinal Biotech Development, Genefit. Research Grants: AbbVie, Takeda, Janssen and Janssen. SPLT has been a consultant or advisory board member for AbbVie, Ajinomoto, Amgen, Almirall, Asahi, Atlantic, Bioclinica, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Calcico, Celgene, Chemocentryx, Cosmo, Covance, Enterome, Falk, Ferring, Genentech, Gilead, Giuliani SpA, GlaxoSmithKline, Glenmark, Grunenthal, Immunocore, Immunometabolism, Istesso, Janssen, Lexicon, Lilly, Medarex, Merck, MSD, Napp, Neovacs, NovoNordisk, Novartis, NPS Pharmaceuticals, Ocera, Otsuka, Pfizer, PharmOlam, Phillips, Proximagen, Qunitiles, Receptos, Robarts, Roche, Sandoz, Shire, Sigmoid Pharma, Takeda, Theravance, TiGenix, Topivert, UCB, Warner Chillcott, Vertex, VHsquared, Vifor and Zeria; speaker for AbbVie, Amgen, Biogen, Ferring, Sandoz, Takeda, Zeria; and received research grants from AbbVie, Buhlmann, Lilly, MediAdd, UCB, Vifor and the Norman Collisson Foundation. PB has received educational grants from AbbVie, Janssens; speaker fees from AbbVie, Takeda and MSD; and advisory board fees from Abbvie, Hospira, Janssen, MSD, Mundipharma, Roche, Pfizer and Dr Falk Benelux. FB has received research grants from Abbvie, Chiesi, Ipsen, MSD, Roche, speakers and consultancy fees from Abbvie, Falk, Ferring, Janssen, Mundipharma, MSD, Pfizer, Takeda, and Vifor. TV has served as advisory member for Hospira, Pfizer and Takeda, has received lecture fees from Takeda. GN has served as a consultant/advisory board member/speaker for AbbVie, MSD, Takeda, Ferring, Vifor, Merck, Janssen and Pfizer. AA has served as a consultant or advisory member for AbbVie, Allergan, Amgen, Biogen, Celgene, Celltrion, Ferring, Hospira, Janssen, Lilly, MSD, Mundipharma, Pfizer, Samsung Bioepis, Sofar and Takeda, has received lecture fees from AbbVie, AstraZeneca, Chiesi, Ferring, Hospira, Medtronic, MSD, Mitsubishi Tanabe, Mundipharma, Nikkiso, Otsuka, Pfizer, Takeda, Tigenix and Zambon, has received research funding from MSD and Takeda. WR has served as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Astellas, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, PLS Education, Schering-Plough, Shire, Takeda, Therakos, Vifor, Yakult; as a consultant for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Roland Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, Elan, Ernest & Young, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, Mallinckrodt, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Robarts Clinical Trial, Schering-Plough, Second Genome, Setpointmedical, Sigmoid, Takeda, Therakos, Tigenix, UCB, Vifor, Zyngenia and 4SC; as an advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zyngenia, and 4SC; and has received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnsotik, and MSD. SJ and MB are employees of Medicus Economics LLC which was paid fees by AbbVie to conduct the research in the manuscript. EN, JP and W-JL are AbbVie employees and may own AbbVie stock and/or options. GRD'H is a consultant for AbbVie, ActoGeniX NV, AGI Therapeutics, Inc, Alba Therapeutics Corporation, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys, Inc, Atlantic Healthcare Limited, Aptalis, BioBalance Corporation, Boehringer Ingelheim, Inc, Bristol-Myers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine PharmaSciences, Eagle Pharmaceuticals, Eisai Medical Research Inc, Elan Pharmaceuticals, enGene, Inc, Eli Lilly, EnteroMedics, Exagen Diagnostics, Inc, Ferring Pharmaceuticals, Flexion Therapeutics, Inc, Funxional Therapeutics Limited, Genzyme Corporation, Genentech, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen, KaloBios Pharmaceuticals, Inc, Lexicon Pharmaceuticals, Lycera Corporation, Meda Pharmaceuticals, Merck Research Laboratories, Merck Serono, Merck & Co., Millennium, Nisshin Kyorin Pharmaceuticals Co, Ltd, Novo Nordisk A/S, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, Inc, PDL BioPharma, Pfizer, Procter & Gamble, Prometheus Laboratories, ProtAb Limited, PurGenesis Technologies, Inc, Receptos, Relypsa, Inc, Salient Pharmaceuticals, Salix Pharmaceuticals, Inc, Santarus, Shire Pharmaceuticals, Sigmoid Pharma Limited, Sirtris Pharmaceuticals, Inc (a GSK company), SLA Pharma (UK) Limited, Targacept, Teva Pharmaceuticals, Therakos, Tillotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Limited (VBL) and Warner Chilcott UK Limited; has received speaker fees from AbbVie, Bristol-Myers Squibb and Janssen; and has received financial support for research from AbbVie, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Millennium, Novartis, Pfizer, Procter & Gamble Pharmaceuticals, Shire Pharmaceuticals and UCB Pharma.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Patient consent for publication:** Not required.
